$APOG

Apogee’s (NASDAQ:APOG) Q3 CY2026: Strong Sales, Stock Jumps 19.7%

Apogee reported Q3 CY2026 revenue of $391.1M, beating estimates by 11.3%. Adjusted EPS of $1.17 exceeded forecasts by 84.3%. The company raised full-year revenue and EPS guidance. Stock rose 19.7%.

Original reporting
Published Oct 6, 2026, 10:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Apogee’s (NASDAQ:APOG) Q3 CY2026: Strong Sales, Stock Jumps 19.7% — source image
Decision brief

The 30-second read

$APOGBullishMed
01

Why it matters

The earnings beat and raised guidance are likely to attract momentum traders and may trigger analyst upgrades.

02

Market read

Earnings beat and guidance raise suggest short‑term upside for APOG.

03

What to watch

Potential supply‑chain constraints or upcoming contract losses not disclosed.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Apogee (NASDAQ:APOG) is a small‑cap aerospace component maker; its earnings surprise is notable for the sector.

Company-level read

Ticker impact

$APOGBullishHigh confidence
Context

Apogee reported Q3 2026 results beating revenue and EPS estimates and raised full-year guidance.

Expected impact

likely upward pressure as the market prices in the beat and higher guidance

Evidence & confidence

Revenue and EPS both exceeded expectations, and guidance was increased, which typically drives buying interest.

Market effects

Positive earnings may lift peers in the same niche of aerospace/defense technology.

Limited to U.S. small‑cap segment; no broad regional effect.

Minimal global impact beyond niche investors.

Counterpoint

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Apogee

    Issuer of the earnings report.

Related articles

$LWHighAI 8/10

US Stock Movers: Lamb Weston, Option Care, Apogee Rally

Lamb Weston (LW) shares rose 11.85% after reporting Q1 sales of $1.67B and raising 2027 EBITDA guidance. Option Care (OPCH) jumped 32.8% on a $5.8B take-private deal. Apogee (APOG) gained 18.7% on strong Q2 earnings and raised FY2027 outlook. Constellation (CEG) surged 14.79% after a Google nuclear deal. RPM (RPM) rose 2.5% on record Q1 results.

$APOGHighAI 8/10

Apogee (APOG) Q2 2027 Earnings Call Transcript

Apogee (APOG) reported Q2 2027 earnings with net sales up 9.2% to $391.1M, driven by acquisitions and pricing. Adjusted EBITDA margin rose to 12.7%, and EPS increased 19% to $1.17. The company highlighted progress in metals, services, and glass segments, with services delivering 10 consecutive quarters of growth. Acquisitions of Kalwall and GrowGlass are expected to enhance capabilities and profitability. Management expressed confidence in long-term growth and shareholder value creation.

$APOGMedAI 8/10

Apogee Enterprises Inc (APOG) (Q2 2027) Earnings Call Highlights: Raised Guidance

Apogee Enterprises (APOG) reported Q2 2027 revenue of $391M, up 9% YoY, and adjusted EPS of $1.17, up 19%. The company raised its fiscal 2027 outlook due to strong first-half performance. Segment performance varied, with Services growing for the 10th consecutive quarter, while Glass and Performance Surfaces faced challenges. Acquisitions of Kalwall and Groglass are progressing well. Leverage ratio is 1.7 times, slightly above target. The company repurchased $6.4M of stock in Q2.

$APOGHighAI 8/10

Apogee raises fiscal 2027 guidance after second-quarter sales rise

Apogee Enterprises (APOG) reported a 9.2% sales increase to $391.1M in Q2, raising its fiscal 2027 adjusted EPS guidance to $3.00-$3.40 and net sales outlook to $1.46B-$1.50B. Operating income rose 24.5% to $33.5M, while net earnings fell 5.4% to $22.4M. Growth was driven by acquisitions, pricing, and product mix, though offset by lower volume and higher costs.